(NAFLD) in adults, with a focus on metabolic, inflammatory, and hepatic biomarkers. Digestive System
Conditions
Interventions
Prospective participants will be drawn from a pool of adult patients with Diabetes Mellitus Type 2 who are monitored at the Principal Investigator's private practice in the city of Heraklion, Crete, a
Sponsors
University of Crete
Eligibility
Sex/Gender
All
Age
30 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1. Adults with a Diagnosis of Diabetes Mellitus Type 2 2. The ability and willingness to provide written informed consent 3. The ability to comply with the study procedures and assessments
Exclusion criteria
Exclusion criteria: 1. Evidence of liver disease of other aetiology (e.g. viral hepatitis, autoimmune liver disease, alcoholic liver disease) 2. Known allergies or hypersensitivity to components of the investigational product (Prunus mume extract and Choline) 3. Known severe Renal Disease or Severe Chronic Heart Failure 4. Active neoplasms or a history of cancer other than hepatocellular carcinoma 5. Taking medication that may affect choline metabolism or cause liver damage 6. Pregnancy or breastfeeding, or intention to become pregnant during the study period 7. Participation in another clinical or interventional study within a recent period prior to enrolment
Countries
Greece
Contacts
Public ContactIoanna Mixaki
Outcome results
None listed